Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 260

1.

Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib.

Park JH, Kim TM, Keam B, Jeon YK, Lee SH, Kim DW, Chung DH, Kim YT, Kim YW, Heo DS.

Clin Lung Cancer. 2013 Jul;14(4):383-9. doi: 10.1016/j.cllc.2012.10.007. Epub 2013 Jan 10.

PMID:
23313171
2.

Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced non-small-cell lung cancer.

Sun HB, Ou W, Li Y, Fang Q, Qin J, Zhang L, Wang SY.

Clin Lung Cancer. 2013 Jul;14(4):376-82. doi: 10.1016/j.cllc.2012.10.008. Epub 2013 Jan 4.

PMID:
23291256
3.

Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.

Zhang L, Yuan X, Chen Y, Du XJ, Yu S, Yang M.

Gene. 2013 Mar 15;517(1):60-4. doi: 10.1016/j.gene.2012.12.087. Epub 2013 Jan 9.

PMID:
23313300
4.
5.

A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.

Pallis AG, Voutsina A, Kentepozidis N, Giassas S, Papakotoulas P, Agelaki S, Tryfonidis K, Kotsakis A, Vamvakas L, Vardakis N, Georgoulias V.

Clin Lung Cancer. 2012 Mar;13(2):129-35. doi: 10.1016/j.cllc.2011.08.004. Epub 2011 Oct 14.

PMID:
22000696
6.

Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.

Asami K, Koizumi T, Hirai K, Ameshima S, Tsukadaira A, Morozumi N, Morikawa A, Atagi S, Kawahara M.

Clin Lung Cancer. 2011 Nov;12(6):387-92. doi: 10.1016/j.cllc.2011.02.004. Epub 2011 May 10.

PMID:
21729650
7.

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS.

J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.

8.

Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.

Okuma Y, Hosomi Y, Nagamata M, Yamada Y, Sekihara K, Kato K, Hishima T, Okamura T.

Anticancer Res. 2013 Nov;33(11):5057-64.

PMID:
24222150
9.

Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene.

Krawczyk P, Kowalski DM, Krawczyk KW, Szczyrek M, Mlak R, Rolski A, Szudy A, Kieszko R, Winiarczyk K, Milanowski J, Krzakowski M.

Oncol Rep. 2013 Sep;30(3):1463-72. doi: 10.3892/or.2013.2553. Epub 2013 Jun 19.

PMID:
23783797
10.
11.

First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.

Wu JY, Yu CJ, Yang CH, Wu SG, Chiu YH, Gow CH, Chang YC, Hsu YC, Wei PF, Shih JY, Yang PC.

Am J Respir Crit Care Med. 2008 Oct 15;178(8):847-53. doi: 10.1164/rccm.200803-389OC. Epub 2008 Jun 26.

PMID:
18583573
12.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.

J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Epub 2008 May 5. Erratum in: J Clin Oncol. 2008 Jul 10;26(20):3472.

13.

The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.

Zhang XT, Li LY, Mu XL, Cui QC, Chang XY, Song W, Wang SL, Wang MZ, Zhong W, Zhang L.

Ann Oncol. 2005 Aug;16(8):1334-42. Epub 2005 Jun 14.

14.

Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer.

Ikeda T, Nakamura Y, Yamaguchi H, Tomonaga N, Doi S, Nakatomi K, Iida T, Motoshima K, Mizoguchi K, Nagayasu T, Tsukamoto K, Kohno S.

Clin Lung Cancer. 2012 Sep;13(5):369-74. doi: 10.1016/j.cllc.2012.01.008. Epub 2012 Mar 10.

PMID:
22410386
15.

Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations.

Yoshida K, Yatabe Y, Park J, Ogawa S, Park JY, Shimizu J, Horio Y, Matsuo K, Mitsudomi T, Hida T.

J Cancer Res Clin Oncol. 2010 Apr;136(4):527-35. doi: 10.1007/s00432-009-0685-2. Epub 2009 Sep 24.

PMID:
19777258
16.

Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.

Wu KL, Tsai MJ, Yang CJ, Chang WA, Hung JY, Yen CJ, Shen CH, Kuo TY, Lee JY, Chou SH, Liu TC, Chong IW, Huang MS.

Lung Cancer. 2015 May;88(2):187-94. doi: 10.1016/j.lungcan.2015.02.012. Epub 2015 Feb 23.

PMID:
25747806
17.

Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.

Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, Nishio K.

Clin Cancer Res. 2006 Jul 1;12(13):3915-21.

18.

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).

Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP.

J Thorac Oncol. 2012 Oct;7(10):1490-502.

19.

EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.

Malapelle U, Bellevicine C, De Luca C, Salatiello M, De Stefano A, Rocco D, de Rosa N, Vitiello F, Russo S, Pepe F, Iaccarino A, Micheli P, Illiano A, Carlomagno C, Piantedosi FV, Troncone G.

Cancer Cytopathol. 2013 Oct;121(10):552-60. doi: 10.1002/cncy.21322. Epub 2013 Jun 18.

20.
Items per page

Supplemental Content

Write to the Help Desk